- Ongoing, recruitingTherapeutic confirmatory (Phase III)
ISIS 678354-CS6 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia
This study is testing a new medicine, Olezarsen, for people with very high levels of a type of fat in their blood called triglycerides. We want to see if it helps lower these levels and prevent related health problems.
For: Severe hypertryglyceridemiaFrance · Italy · Hungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
ISIS 678354-CS9: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) in Patients with Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), or with Severe Hypertriglyceridemia
This study is testing a new medicine, Olezarsen, for people with high 'triglycerides' (a type of fat in the blood) and heart problems. It aims to see if the medicine can lower these fats and is safe to use.
For: Hypertriglyceridemia · Cardiovascular Diseases · AtherosclerosisDenmark · Spain · France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
ISIS 678354-CS5: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia.
This study is testing a new medicine, ISIS 678354, for people with very high levels of a type of fat in their blood called triglycerides. It aims to see if the medicine can lower these levels compared to a dummy medicine.
For: Severe Hypertriglyceridemia.Finland · Germany · Poland